GleamWall
中文EN

SMMT Summit Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1599298 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY15.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-220.0%
ROA-174.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-64.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$169.13M$157.73M$132.62M$147.29M$131.10M$208.02M$51.27M$51.38M
SG&A expense$45.48M$62.76M$62.59M$77.63M$103.11M$360.42M$15.59M$14.23M
Operating income———————-$65.61M
Interest expense———$0$0$0$0$9,000
Net income-$208.38M-$215.70M-$189.42M-$219.17M-$231.79M-$565.71M-$62.91M-$61.20M
EBITDA———————-$65.59M
EPS (basic)-0.26-0.28-0.24—-0.31-0.76-0.09—
EPS (diluted)-0.26-0.28-0.24—-0.31-0.76-0.09—
Weighted avg. shares (diluted)798.20M778.18M775.46M—743.42M742.62M738.08M—
Balance sheet
Cash & equivalents$150.81M$419.37M$106.52M$225.27M$238.55M$297.87M$211.53M$105.19M
Short-term investments$478.98M$271.31M$492.22M$488.18M$0$0$149.79M$307.49M
Current assets$660.73M$720.58M$616.60M$720.30M$246.47M$309.24M$370.75M$423.75M
PP&E, net$2.53M$1.78M$1.66M$1.06M$810,000$690,000$652,000$254,000
Goodwill$1.98M$1.97M$1.97M$2.00M$2.00M$2.04M$1.92M$1.86M
Intangibles———————$0
Total assets$692.85M$752.18M$647.86M$751.18M$261.73M$324.04M$383.82M$435.56M
Current liabilities$110.23M$103.57M$83.27M$72.99M$64.93M$60.33M$34.88M$41.73M
Total liabilities$128.17M$122.20M$101.92M$92.32M$69.47M$64.60M$39.49M$46.81M
Shareholders' equity$564.68M$629.98M$545.93M$658.86M$192.26M$259.44M$344.33M$388.75M
Shares outstanding799.73M793.12M776.02M775.37M744.44M742.81M741.61M737.63M
Cash flow statement
Operating cash flow-$159.81M-$141.12M-$122.29M-$101.94M-$93.08M-$66.74M-$61.17M-$48.67M
Capital expenditure$396,000$909,000$245,000$164,000$71,000$0$422,000$14,000
Free cash flow-$160.21M-$142.03M-$122.54M-$102.10M-$93.15M-$66.74M-$61.59M-$48.69M
Investing cash flow-$204.16M$222.90M-$238,000-$485.16M-$71,000$150.81M$160.11M$83.48M
Financing cash flow$95.43M$231.08M$3.80M$573.82M$33.81M$2.22M$7.68M-$23.61M
Depreciation & amortization$85,000$46,000$44,000$42,000$42,000$37,000$25,000$22,000
Stock-based compensation$47.69M$68.71M$72.79M$111.78M$130.76M$478.78M$11.10M$11.02M

Free plan shows the latest 8 periods; Pro shows all 40 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.